NASDAQ:VVOS Vivos Therapeutics (VVOS) Stock Price, News & Analysis $5.12 +0.14 (+2.81%) (As of 05:35 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Vivos Therapeutics Stock (NASDAQ:VVOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vivos Therapeutics alerts:Sign Up Key Stats Today's Range$4.01▼$5.2450-Day Range$2.44▼$4.9852-Week Range$1.91▼$12.83Volume685,634 shsAverage Volume458,993 shsMarket Capitalization$24.76 millionP/E RatioN/ADividend YieldN/APrice Target$6.30Consensus RatingBuy Company OverviewVivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.Read More… Vivos Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks38th Percentile Overall ScoreVVOS MarketRank™: Vivos Therapeutics scored higher than 38% of companies evaluated by MarketBeat, and ranked 508th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingVivos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVivos Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Vivos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vivos Therapeutics are expected to grow in the coming year, from ($3.13) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vivos Therapeutics is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vivos Therapeutics is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVivos Therapeutics has a P/B Ratio of 23.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.65% of the float of Vivos Therapeutics has been sold short.Short Interest Ratio / Days to CoverVivos Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos Therapeutics has recently decreased by 12.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVivos Therapeutics does not currently pay a dividend.Dividend GrowthVivos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.65% of the float of Vivos Therapeutics has been sold short.Short Interest Ratio / Days to CoverVivos Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vivos Therapeutics has recently decreased by 12.23%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News Sentiment1.00 News SentimentVivos Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vivos Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for VVOS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vivos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Vivos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 26.35% of the stock of Vivos Therapeutics is held by institutions.Read more about Vivos Therapeutics' insider trading history. Receive VVOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vivos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VVOS Stock News HeadlinesVivos to sell 709,220 shares at $4.935 in registered direct offeringDecember 23 at 10:11 PM | markets.businessinsider.comVivos Therapeutics announces funding boostDecember 23 at 9:25 AM | proactiveinvestors.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 23, 2024 | Behind the Markets (Ad)Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesDecember 23 at 8:00 AM | globenewswire.comVivos Therapeutics price target lowered to $6 from $8.25 at Alliance Global PartnersNovember 19, 2024 | markets.businessinsider.comVivos Therapeutics Inc (VVOS) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...November 16, 2024 | finance.yahoo.comVivos Therapeutics Reports Revenue Growth and Strategic MilestonesNovember 16, 2024 | markets.businessinsider.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comSee More Headlines VVOS Stock Analysis - Frequently Asked Questions How have VVOS shares performed this year? Vivos Therapeutics' stock was trading at $12.44 at the start of the year. Since then, VVOS shares have decreased by 58.8% and is now trading at $5.12. View the best growth stocks for 2024 here. How were Vivos Therapeutics' earnings last quarter? Vivos Therapeutics, Inc. (NASDAQ:VVOS) released its quarterly earnings data on Monday, November, 15th. The company reported ($6.50) earnings per share for the quarter, missing the consensus estimate of ($4.00) by $2.50. The business had revenue of $4.55 million for the quarter, compared to analyst estimates of $4.50 million. Vivos Therapeutics had a negative net margin of 86.19% and a negative trailing twelve-month return on equity of 335.04%. When did Vivos Therapeutics' stock split? Vivos Therapeutics shares reverse split on Friday, October 27th 2023. The 1-25 reverse split was announced on Friday, October 27th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 27th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Vivos Therapeutics IPO? Vivos Therapeutics (VVOS) raised $20 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 3,300,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners acted as the underwriter for the IPO and Craig-Hallum Capital Group and National Securities Corporation were co-managers. Who are Vivos Therapeutics' major shareholders? Top institutional investors of Vivos Therapeutics include Strategic Wealth Investment Group LLC (2.10%). View institutional ownership trends. How do I buy shares of Vivos Therapeutics? Shares of VVOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vivos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vivos Therapeutics investors own include Meta Platforms (META), NIO (NIO), Pfizer (PFE), Plug Power (PLUG), Advanced Micro Devices (AMD), Aridis Pharmaceuticals (ARDS) and Cocrystal Pharma (COCP). Company Calendar Last Earnings11/15/2021Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:VVOS CUSIPN/A CIK1716166 Webwww.vivoslife.com Phone866-908-4867FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$6.30 High Stock Price Target$6.60 Low Stock Price Target$6.00 Potential Upside/Downside+23.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,580,000.00 Net Margins-86.19% Pretax Margin-86.19% Return on Equity-335.04% Return on Assets-93.58% Debt Debt-to-Equity RatioN/A Current Ratio1.44 Quick Ratio1.44 Sales & Book Value Annual Sales$14.58 million Price / Sales1.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book23.27Miscellaneous Outstanding Shares4,835,000Free Float4,690,000Market Cap$24.76 million OptionableOptionable Beta7.67 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:VVOS) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.